한국콜마 자회사 HK이노엔, 970억 규모 신규 시설투자

HK이노엔's 97 billion won investment signals Korean contract manufacturer Kolmar Korea's strategy to expand production capacity for solid dosage forms. This capacity expansion is a long-term growth initiative to capture increasing market demand and enhance global competitiveness in the pharmaceutical and cosmetics manufacturing sector. The investment reflects the growing importance of CMOs in supporting global supply chains and the industry's expansion trajectory.